Department of Surgery »  Faculty »  General Surgery »  Wen T. Shen, M.D., M.A.

Wen T. Shen, M.D., M.A.

Associate Professor of Clinical Surgery
Division of General Surgery

Contact Information

Campus Box 1674
University Of California San Francisco
Mt. Zion Medical Center
Hellman Bldg. Room C-349
San Francisco, CA 94115
415-885-3755 (Academic Office)
415-353-7687 (Clinic)
415-885-7617 (Fax)
Wen.Shen2@ucsf.edu
Open Popup
  • 1990-94, Harvard University, B.A., History and Science
  • 1994-99, University of California, San Francisco School of Medicine, M.D. with thesis
  • 2007-2009, University of California, San Francisco, M.A., History of Medicine
  • 1999-02 University of California San Francisco School of Medicine, Resident, Surgery
  • 2005-06 University of California San Francisco School of Medicine, Resident, Surgery
  • 2006-07 University of California San Francisco School of Medicine, Chief Resident, Surgery
  • 2002-05 University of California San Francisco School of Medicine, Research Fellow in Endocrine Surgical Oncology
  • American Board of Surgery
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • San Francisco Veterans' Affairs Medical Center
  • Biomarkers of cardiovascular risk in primary hyperparathyroidism
  • Genetic profiles of adrenal metastases from solid organ and skin cancers
  • History of surgery
  • Minimally invasive endocrine surgery
  • Role of matrix metalloproteinases in thyroid cancer
  • Use of novel anti-neoplastic agents to treat thyroid cancer, including direct MMP inhibitors, histone deacetylase inhibitors, PPAR-gamma agonists, and demethylating agents.

Wen T. Shen, M.D., M.A. is an endocrine surgeon specializing in procedures for thyroid, parathyroid and adrenal gland surgery. His research focuses on the molecular biology, genetics and treatment of thyroid cancer as well as the use of minimally invasive surgery. Shen also has an interest in medical history and has studied the development of hormonal therapies for benign and malignant conditions and the impact of the 1942 Coconut Grove Fire in Boston on the evolution of surface treatment for burns. 

Dr. Shen graduated magna cum laude at Harvard College, where he earned a bachelor's degree in history and science. He earned a medical degree and completed a surgical residency and research fellowship in endocrine surgery at UCSF. He received the Esther Nusz Achievement Award from the UCSF Department of Surgery, Resident's Prize from the Pacific Coast Surgical Association, William Osler Medal from the American Association for the History of Medicine and Rothschild Prize from the Department of the History of Science at Harvard University.

In 2016, Dr. Shen was elected the 67th President of the UCSF Naffziger Surgical Society for its 2016-2017 term.

Dr. Shen's basic science research is focused on the molecular biology and genetic underpinnings of thyroid cancer. He is particularly interested in the redifferentiation and growth inhibitory effects of novel anti-tumor agents such as PPAR-gamma agonists and histone deacetylase (HDAC) inhibitors in thyroid cancer. Dr. Shen is investigating the effects of modulating matrix metalloproteinase (MMP) activity as a strategy for treating thyroid cancer. He is also studying the genetic profiles of adrenal metastases from solid organ and skin cancers.

Dr. Shen's current clinical research interests include predictors of lymph node metastases in papillary thyroid cancer, treatment of adrenal metastases from solid organ and skin cancers, the development of minimally invasive endocrine surgical techniques, and the impact of primary hyperparathyroidism on cardiovascular health and aging.

Dr. Shen's research has been generously funded by grants from the American College of Surgeons, the James Ewing Foundation through the Society of Surgical Oncology, the University of California Cancer Research Coordinating Committee, and the UCSF Resource Allocation Program.

In addition to his basic and clinical research, Dr. Shen maintains a strong interest in the history of surgery. Topics of his historical research have included the use of DES and other hormonal therapies in the 1950s, the 1942 Coconut Grove Fire in Boston and its impact on burn care, and the history of adrenal incidentaloma. He holds a masters' degree in the History of Medicine from the UCSF Department of Anthropology, History and Social Medicine. 

Insoo Suh, M.D.
  1. Siperstein AE, Shen W, Chan AK, Duh QY, Clark OH. Normocalcemic hyperparathyroidism: biochemical and symptom profiles before and after surgery. Arch Surg, 10/1992;127:1157-63.
  2. Tezelman S, Shen W, Shaver JK, Siperstein AE, Duh QY, Klein H, Clark OH. Double parathyroid ademonas: clinical and biochemical characteristics before and after parathyroidectomy. Ann Surg, 09/1993;218:300-9.
  3. Tezelman S, Rodriguez JM, Shen W, Siperstein AE, Duh Qy, Clark OH. Primary hyperparathyroidism in patients who have received radiation therapy and in patients who have not received radiation therapy. J Am Coll Surg, 01/1995;180:81-87.
  4. Tezelman S, Shen W, Siperstein AE, Duh Qy, Clark OH. Persistent or recurrent hyperparathyroidism in patients with double adenomas. Surgery, 12/1995;118:1115-24.
  5. Shen W, Duren M, Morita ET, Higgins C, Duh QY, Siperstein AE, Clark OH. Reoperation for persistent or recurrent primary hyperparathyroidism. Arch Surg, 08/1996;131:861-9.
  6. Shen W, Sabanci U, Morita ET, Siperstein AE, Duh Qy, Clark OH. Sestamibi scanning is inadequate for directing unilateral neck exploration for first-time parathyroidectomy. Arch Surg, 09/1997;132:969-76.
  7. Shen WT, Lim RC, Siperstein AE, Clark OH, Schecter WP, Hunt TK, Horn JK, Duh QY. Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Arch Surg, Jun/1999;134(6):628-31; discussion 631-2.
  8. Duren M, Siperstein AE, Shen W, Duh QY, Morita E, Clark OH. Value of stimulated serum thyrogloblin levels for detecting persistent or recurrent differentiated thyroid cancer in high-and-low risk patients. Surgery, 07/1999;126:13-9.
  9. Sebag F, Shen W, Brunaud L, Kebebew E, Duh QY, Clark OH. Intraoperative parathyroid hormone assay and parathyroid reoperations. Surgery, 12/2003;134:1049-56.
  10. Shen WT, Kebebew E, Duh QY, Clark OH. Predictors of airway complications after thyroidectomy for substernal goiter. Arch Surg, Jun/2004;139(6):656-9; discussion 659-60.
  11. Shen WT, Kebebew E, Clark OH, Duh QY. Reasons for conversion from laparoscopic to open or hand-assisted adrenalectomy: review of 261 laparoscopic adrenalectomies from 1993 to 2003. World J Surg, Nov/2004;28(11):1176-9.
  12. Shen WT, Sturgeon C, Clark OH, Duh QY, Kebebew E. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery, Dec/2004;136(6):1129-37.
  13. Shen WT, Baumbusch MA, Kebebew E, Duh QY. Use of the electrothermal vessel sealing system versus standard vessel ligation in thyroidectomy. Asian J Surg, Apr/2005;28(2):86-9.
  14. Shen WT, Wong TS, Chung WY, Wong MG, Kebebew E, Duh QY, Clark OH. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. Surgery, Dec/2005;138(6):979-84; discussion 984-5.
  15. Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg, Mar/2006;202(3):423-30.
  16. Shen WT, Lee J, Kebebew E, Clark OH, Duh QY. Selective use of steroid replacement after adrenalectomy: lessons from 331 consecutive cases. Arch Surg, Aug/2006;141(8):771-4; discussion 774-6.
  17. Lee JA, Zarnegar R, Shen WT, Kebebew E, Clark OH, Duh QY. Adrenal incidentaloma, borderline elevations of urine or plasma metanephrine levels, and the "subclinical" pheochromocytoma. Arch Surg, Sep/2007;142(9):870-3; discussion 73-4.
  18. Shen WT. A Brief History of Orlo H. Clark. World J Surg, Aug/26/2008.
  19. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, Sturgeon C. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer, Dec/1/2008;113(11):3130-6.
  20. Ruan DT, Warren RS, Moalem J, Chung KW, Griffin AC, Shen W, Duh QY, Nakakura E, Donner DB, Khanafshar E, Weng J, Clark OH, Kebebew E. Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers. Surgery, Dec/2008;144(6):908-13; discussion 913-4.
  21. Moalem J, Ruan DT, Farkas RL, Shen WT, Gosnell JE, Miller S, Duh QY, Clark OH, Kebebew E. Hemolysis falsely decreases intraoperative parathyroid hormone levels. Am J Surg, Dec/16/2008.
  22. Shen WT, Kebebew E, Suh I, Duh QY, Clark OH. Two hundred and two consecutive operations for secondary hyperparathyroidism: has medical management changed the profiles of patients requiring parathyroidectomy? Surgery, Aug/2009;146(2):296-9.
  23. Guerrero MA, Schreinemakers JM, Vriens MR, Suh I, Hwang J, Shen WT, Gosnell J, Clark OH, Duh QY. Clinical spectrum of pheochromocytoma. J Am Coll Surg, Dec/2009;209(6):727-32.
  24. Suh I, Filetti S, Vriens MR, Guerrero MA, Tumino S, Wong M, Shen WT, Kebebew E, Duh QY, Clark OH. Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families. Surgery, Dec/2009;146(6):1073-80.

 

X